Is Feburic (febuxostat) safe to use during breastfeeding?

Feburic (Febuxostat) and Breastfeeding

Direct Recommendation

Febuxostat should be avoided during breastfeeding due to the absence of safety data and the known risk of severe drug interactions with azathioprine, which is commonly used in rheumatic conditions and is compatible with breastfeeding. 1

---

Evidence-Based Rationale

Lack of Safety Data

• No clinical data exist on febuxostat excretion into human breast milk or its effects on breastfed infants. 2
• The FDA drug label for febuxostat does not provide information regarding its use during lactation, indicating insufficient evidence to establish safety. 2
• When drugs lack breastfeeding safety data and safer alternatives exist, they should be avoided until further evidence becomes available. 1

Critical Drug Interaction Concerns

• Febuxostat, as a xanthine oxidase inhibitor, carries a substantially increased risk of life-threatening myelotoxicity when combined with azathioprine or other thiopurines. 1
• This interaction is particularly relevant because azathioprine is strongly recommended as compatible with breastfeeding for rheumatic and musculoskeletal diseases. 1
• The British Association of Dermatologists explicitly warns that combined use of xanthine oxidase inhibitors (including febuxostat) with azathioprine requires strict monitoring and dose reduction, and should be considered experimental. 1

Alternative Management Strategies

• For gout management during breastfeeding, colchicine is strongly recommended as compatible with breastfeeding and should be the preferred agent. 1
• Colchicine has established safety data in lactating women with rheumatic and musculoskeletal diseases. 1
• NSAIDs are conditionally recommended as compatible with breastfeeding and may be used for acute gout flares. 1

---

Clinical Decision Algorithm

1. If treating gout during breastfeeding:

   • First-line: Use colchicine for acute flares or prophylaxis 1
   • Second-line: Consider short-term NSAIDs (conditionally compatible) 1
   • Avoid: Febuxostat due to lack of safety data 1, 2

2. If patient is already on febuxostat and wishes to breastfeed:

   • Discontinue febuxostat before initiating breastfeeding 1
   • Switch to colchicine for gout management 1
   • Wait until febuxostat is cleared from maternal system (approximately 5 half-lives = 2-3 days) before breastfeeding

3. If patient is on concurrent azathioprine therapy:

   • Never combine febuxostat with azathioprine in any clinical context 1
   • Continue azathioprine (strongly compatible with breastfeeding) 1
   • Use colchicine for gout management instead 1

---

Important Caveats

General Principles for Medication During Lactation

• The relative infant dose (drug amount in breast milk divided by maternal dose, normalized per kg) should be <10% to be considered safe. 1
• Most medications transfer into breast milk based on concentration gradients, favoring non-ionized, non-protein-bound drugs. 3
• Premature or compromised infants may require additional consideration due to altered drug metabolism and potential accumulation. 3

Common Pitfall to Avoid

• Do not assume that drugs safe during pregnancy are automatically safe during breastfeeding. 3
• Febuxostat's lack of data during lactation means it falls into the category of drugs that should be avoided until further evidence is available, similar to other agents like leflunomide and mycophenolate. 1